Navigation Links
Ovalum Ltd. Announces Success in Coronary Cases Using CiTop™ ExPander™ Guidewire
Date:7/11/2008

Following First-in-Man study success, Ovalum Ltd. launches a multicenter study using the CiTop™ technology in the coronary arteries. Ovalum Ltd., a privately held Israeli medical device company, has announced today successful experiences using CiTop™ ExPander™ Guidewire in traversing chronic total occlusions in the coronary arteries.

Rehovot , Israel (PRWEB) July 11, 2008 -- Following First-in-Man study success, Ovalum Ltd. launches a multicenter study using the CiTop™ technology in the coronary arteries.

Ovalum Ltd., a privately held Israeli medical device company, has announced today successful experiences using CiTop™ ExPander™ Guidewire in traversing chronic total occlusions in the coronary arteries.

Chronic Total Occlusion (CTO) is one of the main challenges that Interventional Cardiologists face today. Attempts in opening coronary CTOs by using mechanical wires are ranging from 26% to 85% and are operator dependent. In order to increase success rate and make it less operator-dependent, the CiTop™ ExPander™ Guidewire was designed. The CiTop™ ExPander™ Guidewire is a 0.014" Guidewire which combines conventional guidewire navigational properties with a tip dilation feature to aid in releasing a wedged guidewire and allow its advancement through difficult occlusions.

The company has completed successfully its First-in-Man study in the use of the CiTop™ ExPander™ Guidewire in the coronary arteries. Dr. Keyur H. Parikh, The Heart Care Clinic/Care Cardiovascular Consultants (Ahmedabad, India), Principle Investigator of the study has said: "Ovalum with its CiTop™ wire has discovered an approach to a safe and sure way to cross CTOs. Chronic Total Occlusions is one of the last frontiers of the Cardiologists, the CiTop™ wire has shown me an approach towards that last frontier.... "

Ovalum is launching this July its Multicenter study to evaluate the performance of the CiTop™ ExPander™ Guidewire in crossing CTOs in the coronary arteries. Dr. Farrel Hellig from the Sunninghill Hospital in Johannesburg, South Africa, has concluded that "…the CiTop™ was successful with an excellent result" after an initial experience with the CiTop™ ExPander™ Guidewire.

The company has submitted the CiTop™ ExPander™ Guidewire to its notified body in the European Economic Area and is expecting to receive its CE marking during the fourth quarter of 2008. In addition, the company has completed the CiTop™ ExPander™ Guidewire 510K application to the FDA which will be submitted next month.

The CiTop™ ExPander™ Guidewire provides a simpler and more efficient means to open the Chronic Total Occlusion, thus avoiding the need for coronary bypass surgery. Noam Shamay, founder and CEO of Ovalum Ltd. said: "I am enthusiastic about the opportunity to introduce a significantly less invasive therapeutic option for coronary CTO patients".

About Ovalum

Ovalum Ltd. was founded in March 2005 by Noam Shamay and Eitan Finkelstein. Located in Rabin Science Park Rehovot, Israel, OVALUM Ltd. Develops, manufactures and markets breakthrough products for the minimally invasive cardiology and interventional radiology markets designed specifically for the most challenging arterial procedures.

Ovalum Ltd. investors: Ziegler Meditech equity Partners LP and Smithfield Fiduciary LLC, represented by Eitan Machover (Director) and Pontifax LP represented by Tomer Kariv (Director).

CiTop™, CoBra™, TraVerse™ are all trademarks of Ovalum Ltd.

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe
2. Ovalum Ltd. Received Clearance to Market the CiTop™ Product-Line in Israel
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee is ... honoring scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. ... world’s leading conference and exposition for laboratory science, which will be held February ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System ... standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography ...
(Date:10/6/2017)... ... October 06, 2017 , ... On ... and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The ... The event is free and open to the public, but registration is required. ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):